Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016

  • ID: 3837891
  • Company Profile
  • Region: Global
  • 90 pages
  • Global Markets Direct
  • Valeant
1 of 4
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016

Summary

‘Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016’, provides an overview of the Valeant Pharmaceuticals International, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc.
- The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Valeant Pharmaceuticals International, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Valeant Pharmaceuticals International, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Valeant Pharmaceuticals International, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Valeant Pharmaceuticals International, Inc. Snapshot

Valeant Pharmaceuticals International, Inc. Overview

Key Information

Key Facts

Valeant Pharmaceuticals International, Inc. - Research and Development Overview

Key Therapeutic Areas

Valeant Pharmaceuticals International, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance

Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Valeant Pharmaceuticals International, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

Valeant Pharmaceuticals International, Inc. - Drug Profiles

brodalumab

Product Description

Mechanism of Action

R&D Progress

(halobetasol propionate + tazarotene)

Product Description

Mechanism of Action

R&D Progress

budesonide

Product Description

Mechanism of Action

R&D Progress

IDP-122

Product Description

Mechanism of Action

R&D Progress

loteprednol etabonate next generation

Product Description

Mechanism of Action

R&D Progress

rifaximin DR

Product Description

Mechanism of Action

R&D Progress

BLO-020

Product Description

Mechanism of Action

R&D Progress

ezogabine

Product Description

Mechanism of Action

R&D Progress

IDP-120

Product Description

Mechanism of Action

R&D Progress

IDP-121

Product Description

Mechanism of Action

R&D Progress

IDP-125

Product Description

Mechanism of Action

R&D Progress

IDP-126

Product Description

Mechanism of Action

R&D Progress

IDP-127

Product Description

Mechanism of Action

R&D Progress

IDP-128

Product Description

Mechanism of Action

R&D Progress

IDP-129

Product Description

Mechanism of Action

R&D Progress

IDP-130

Product Description

Mechanism of Action

R&D Progress

IDP-131

Product Description

Mechanism of Action

R&D Progress

lapuleucel-T

Product Description

Mechanism of Action

R&D Progress

ribavirin

Product Description

Mechanism of Action

R&D Progress

SAL-021

Product Description

Mechanism of Action

R&D Progress

Product Description

Mechanism of Action

R&D Progress

SPT-201

Product Description

Mechanism of Action

R&D Progress

metyrosine

Product Description

Mechanism of Action

R&D Progress

BLO-021

Product Description

Mechanism of Action

R&D Progress

IDP-123

Product Description

Mechanism of Action

R&D Progress

IDP-124

Product Description

Mechanism of Action

R&D Progress

VALBRO-03

Product Description

Mechanism of Action

R&D Progress

Valeant Pharmaceuticals International, Inc. - Pipeline Analysis

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action

Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates

Valeant Pharmaceuticals International, Inc. - Dormant Projects

Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

ATON-004

(bupropion hydrochloride + selective serotonin reuptake inhibitor)

brodalumab

CVTE-002

ezogabine

IDP-107

IDP-109

IDP-115

MC-5

methylnaltrexone bromide

pegaptanib sodium

rifaximin

RUS-350

taribavirin hydrochloride

tiazofurin

UK-279276

Valeant Pharmaceuticals International, Inc. - Company Statement

Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Valeant Pharmaceuticals International, Inc., Key Information

Valeant Pharmaceuticals International, Inc., Key Facts

Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016

Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Combination Treatment Modalities in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Valeant Pharmaceuticals International, Inc. - Pre-Registration, 2016

Valeant Pharmaceuticals International, Inc. - Phase III, 2016

Valeant Pharmaceuticals International, Inc. - Phase II, 2016

Valeant Pharmaceuticals International, Inc. - Phase I, 2016

Valeant Pharmaceuticals International, Inc. - Preclinical, 2016

Valeant Pharmaceuticals International, Inc. - Unknown, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2016

Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2016

Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2016

Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2016

Valeant Pharmaceuticals International, Inc., Other Locations

Valeant Pharmaceuticals International, Inc., Subsidiaries 81List of Figures

Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Indication, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016

Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Target, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016

Valeant Pharmaceuticals International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll